Cite
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
MLA
Ouédraogo, Alphonse, et al. “Safety and Immunogenicity of BK-SE36/CpG Malaria Vaccine in Healthy Burkinabe Adults and Children: A Phase 1b Randomised, Controlled, Double-Blinded, Age de-Escalation Trial.” Frontiers in Immunology, Oct. 2023, pp. 1–17. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1267372.
APA
Ouédraogo, A., Bougouma, E. C., Palacpac, N. M. Q., Houard, S., Nebie, I., Sawadogo, J., Berges, G. D., Soulama, I., Diarra, A., Hien, D., Ouedraogo, A. Z., Konaté, A. T., Kouanda, S., Akira Myoui, Sachiko Ezoe, Ishii, K. J., Takanobu Sato, D’Alessio, F., Leroy, O., & Tiono, A. B. (2023). Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial. Frontiers in Immunology, 1–17. https://doi.org/10.3389/fimmu.2023.1267372
Chicago
Ouédraogo, Alphonse, Edith Christiane Bougouma, Nirianne Marie Q. Palacpac, Sophie Houard, Issa Nebie, Jean Sawadogo, Gloria D. Berges, et al. 2023. “Safety and Immunogenicity of BK-SE36/CpG Malaria Vaccine in Healthy Burkinabe Adults and Children: A Phase 1b Randomised, Controlled, Double-Blinded, Age de-Escalation Trial.” Frontiers in Immunology, October, 1–17. doi:10.3389/fimmu.2023.1267372.